Heterocyclic compounds for cancer imaging and treatment and methods for their use

A pharmaceutical composition, comprising:

• a pharmaceutically acceptable carrier and a compound of formula (I):
• or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
• X is —O—, —S(O)0-2—, —C(═O)—, —C(OR5)2—, —C(OR5)(OC(═O)R13)—, —C(R8R9)—, —C(═CR8R9)—, —N(R9)—, —N(COR9)—, —CHNR8R9—, —C(═NR9)—, —C(═NOR5)—, —C(═N—NHR5)—;
• R1 and R2 are each independently H, hydroxyl, —O-heterocyclyl, or —OC(═O)R13;
• R3 is heterocyclyl which is optionally substituted with one or more R6;
• R5 is each independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
• R6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123I, hydroxyl, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C12 aryl, wherein each R6 is optionally substituted with one or more of halogen, 123I, 18F, hydroxyl, —OS(O)2-aryl, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
• R8 and R9 are each independently H, halogen, —S(O)0-2R5, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, aralkyl, C1-C10 acyl, or —NR5R5, or R8 and R9 can join to form a unsubstituted or substituted mono-, bi-, or tri-cyclic carbocycle or heterocycle containing from 3 to 20 carbon atoms;
• R11a, R11b, R11c and R11d are each independently H, F, Cl, Br, I, 123I, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —OR5, —OC(═O)R13, C1-C10 acyl, —S(O)0-2R5, —NO2, —CN, —NH2, —NHR5, or —N(R5)2;
• R13 is each independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
• n1 and n2 are each independently 0, 1, or 2;
• and
• n3 is 0, 1, 2, 3, 4, or 5.

A method for treating a condition or disease selected from the group consisting of:

• prostate cancer, breast cancer, ovarian cancer, endometrial cancer, salivary gland carcinoma, hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty, spinal and bulbar muscular atrophy, and age-related macular degeneration, comprising:
• administering to a patient in need thereof a compound having the following structure (I):
• or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
• X is —O—, —S(O)0-2—, —C(═O)—, —C(OR5)2—, —C(OR5)(OC(═O)R13)—, —C(R8R9)—, —C(═CR8R9)—, —N(R9)—, —N(COR9)—, —CHNR8R9—, —C(═NR9)—, —C(═NOR5)—, —C(═N—NHR5)—;
• R1 and R2 are each independently H, hydroxyl, —O-heterocyclyl, or —OC(═O)R13;
• R3 is heterocyclyl which is optionally substituted with one or more R6;
• R5 is each independently H, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
• R6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123I, hydroxyl, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C12 aryl, wherein each R6 is optionally substituted with one or more of halogen, 123I, 18F, hydroxyl, —OS(O)2-aryl, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
• R8 and R9 are each independently H, halogen, —S(O)0-2R5, C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl, aryl, aralkyl, C1-C10 acyl, or —NR5R5, or R8 and R9 can join to form a unsubstituted or substituted mono-, bi-, or tri-cyclic carbocycle or heterocycle containing from 3 to 20 carbon atoms;
• R11a, R11b, R11c and R11d are each independently H, F, Cl, Br, I, 123I, hydroxyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, —OR5, —OC(═O)R13, C1-C10 acyl, —S(O)0-2R5, —NO2, —CN, —NH2, —NHR5, or —N(R5)2;
• R13 is each independently C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
• n1 and n2 are each independently 0, 1, or 2;
• and
• n3 is 0, 1, 2, 3, 4, or 5.